학술논문

Safety, immunogenicity and efficacy of peptide-pulsed cellular immunotherapy in macaques.
Document Type
Article
Source
Journal of Medical Primatology. 2008 Suppl 2, Vol. 37, p69-78. 10p. 1 Chart, 3 Graphs.
Subject
Language
ISSN
0047-2565
Abstract
Background Simple and effective delivery methods for cellular immunotherapies are needed. We recently published on the effectiveness of using ex vivo pulsing of overlapping SIV Gag 15mer peptides onto fresh peripheral blood cells in 32 SIVmac251-infected pigtail macaques. Methods We now report on the safety of this approach, analysis of a novel assay for immunogenicity, the effect of an MHC allele, Mane-A*10, on CD8 T cell escape occurring and disease outcome. Results The vaccine strategy was safe, with no perturbations in weight or hematological profiles in comparison to controls. The high levels of SIVspecific T cell immunogenicity of this approach was confirmed using a novel assay measuring upregulation of surface CD134 of CD4 T cells. A substantial effect of the Mane-A*10 allele in reducing SIV viral load of pigtail macaques was observed in both vaccinees and controls; the virologic efficacy of the immunotherapy in comparison to controls was greatest in Mane-A*10) animals. Escape mutations at several new CD8 T cell epitopes throughout the SIV proteome were observed, primarily in animals with poorer virologic control. Conclusions In summary, we provide further information that peptidepulsed PBMC are a safe, immunogenic and effective immunotherapy. The observed influence of MHC alleles and immune escape allows us to design more insightful future immunotherapy studies. [ABSTRACT FROM AUTHOR]